Literature DB >> 18347507

Diagnosing endometrial hyperplasia: why is it so difficult to agree?

Kimberly H Allison1, Susan D Reed, Lynda F Voigt, Carolyn D Jordan, Kathryn M Newton, Rochelle L Garcia.   

Abstract

Current World Health Organization classification of endometrial hyperplasia is problematic because of poor diagnostic reproducibility. We sought to determine factors that cause diagnostic disagreement in a review of 2601 endometrial specimens. Blinded random specimens of normal endometrium, hyperplasias, and carcinoma were reviewed by 2 pathologists, with review by a third pathologist in cases with disagreement. All cases of endometrial hyperplasia or carcinoma were scored for degree of glandular crowding, architectural complexity, and cytologic atypia. Sample adequacy, hyperplasia volume, presence of metaplasia, or endometrial polyp were also scored. The overall kappa for agreement was 0.71, with a lower kappa of 0.36 when cases called "no hyperplasia" were excluded. The percent specific agreement was 90.3% for no hyperplasia, 31.1% for simple hyperplasia, 51.1% for complex hyperplasia, 49.8% for atypical hyperplasia, and 57.5% for adenocarcinoma. Cases categorized as "low volume hyperplasia" had more diagnostic disagreement than "high volume," (62% vs. 39%, P=0.003). Similarly, cases called "scant" had more diagnostic disagreement than "not scant" (65% vs. 57%, P=0.013). The histologic feature associated with the most diagnostic disagreement was cytologic atypia (P<0.0001). Architectural crowding, architectural complexity, or the presence of a polyp were all associated with diagnostic disagreement (P<0.0001). High diagnostic disagreement in endometrial hyperplasia is related to both sample adequacy and interpretation of histologic features present. Although obtaining additional tissue may increase diagnostic reproducibility, differences in interpretation of key histologic features like cytologic atypia remain major factors contributing to diagnostic disagreement.

Entities:  

Mesh:

Year:  2008        PMID: 18347507      PMCID: PMC2682169          DOI: 10.1097/PAS.0b013e318159a2a0

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  21 in total

1.  Molecular identification of latent precancers in histologically normal endometrium.

Authors:  G L Mutter; T A Ince; J P Baak; G A Kust; X P Zhou; C Eng
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group.

Authors:  G L Mutter
Journal:  Gynecol Oncol       Date:  2000-03       Impact factor: 5.482

Review 3.  Histopathology of genetically defined endometrial precancers.

Authors:  G L Mutter
Journal:  Int J Gynecol Pathol       Date:  2000-10       Impact factor: 2.762

Review 4.  Endometrial hyperplasias, precursors of endometrial carcinoma.

Authors:  F Vellios
Journal:  Pathol Annu       Date:  1972

Review 5.  Carcinoma in situ of the endometrium.

Authors:  H Gore; A T Hertig
Journal:  Am J Obstet Gynecol       Date:  1966-01-01       Impact factor: 8.661

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

7.  Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment.

Authors:  L-C Horn; U Schnurrbusch; K Bilek; B Hentschel; J Einenkel
Journal:  Int J Gynecol Cancer       Date:  2004 Mar-Apr       Impact factor: 3.437

8.  The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients.

Authors:  R J Kurman; P F Kaminski; H J Norris
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

9.  Endometrial lesions in uteri resected for atypical endometrial hyperplasia.

Authors:  F Tavassoli; F T Kraus
Journal:  Am J Clin Pathol       Date:  1978-11       Impact factor: 2.493

Review 10.  Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia.

Authors:  George L Mutter; Richard J Zaino; Jan P A Baak; Rex C Bentley; Stanley J Robboy
Journal:  Int J Gynecol Pathol       Date:  2007-04       Impact factor: 2.762

View more
  24 in total

1.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

2.  Stromal p16 expression differentiates endometrial polyp from endometrial hyperplasia.

Authors:  Suzuko Moritani; Shu Ichihara; Masaki Hasegawa; Akari Iwakoshi; Sakae Murakami; Tomoko Sato; Tomomitsu Okamoto; Yoshio Mori; Hajime Kuhara; Steven G Silverberg
Journal:  Virchows Arch       Date:  2012-07-07       Impact factor: 4.064

3.  PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.

Authors:  Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia
Journal:  Int J Gynecol Pathol       Date:  2012-03       Impact factor: 2.762

4.  Incidence of endometrial hyperplasia.

Authors:  Susan D Reed; Katherine M Newton; Walter L Clinton; Meira Epplein; Rochelle Garcia; Kimberly Allison; Lynda F Voigt; Noel S Weiss
Journal:  Am J Obstet Gynecol       Date:  2009-04-23       Impact factor: 8.661

5.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

6.  Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.

Authors:  Anthony B Costales; Kathleen M Schmeler; Russell Broaddus; Pamela T Soliman; Shannon N Westin; Pedro T Ramirez; Michael Frumovitz
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

7.  Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.

Authors:  Omar Habeeb; Lee Goodglick; Robert A Soslow; Rajiv G Rao; Lynn K Gordon; Osvaldo Schirripa; Steve Horvath; Jonathan Braun; David B Seligson; Madhuri Wadehra
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

Review 8.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

9.  Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel.

Authors:  Kimberly H Allison; Lisa M Reisch; Patricia A Carney; Donald L Weaver; Stuart J Schnitt; Frances P O'Malley; Berta M Geller; Joann G Elmore
Journal:  Histopathology       Date:  2014-04-02       Impact factor: 5.087

Review 10.  [Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].

Authors:  F Kommoss; S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.